XOMA Royalty Corporation (XOMA)
NASDAQ: XOMA · Real-Time Price · USD
24.14
-0.09 (-0.37%)
Apr 25, 2025, 4:00 PM EDT - Market closed
XOMA Royalty Revenue
In the year 2024, XOMA Royalty had annual revenue of $28.49M with 498.72% growth. XOMA Royalty had revenue of $8.71M in the quarter ending December 31, 2024, with 375.40% growth.
Revenue (ttm)
$28.49M
Revenue Growth
+498.72%
P/S Ratio
9.92
Revenue / Employee
$2,191,308
Employees
13
Market Cap
288.54M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.49M | 23.73M | 498.72% |
Dec 31, 2023 | 4.76M | -1.27M | -21.06% |
Dec 31, 2022 | 6.03M | -32.13M | -84.21% |
Dec 31, 2021 | 38.16M | 8.78M | 29.86% |
Dec 31, 2020 | 29.39M | 11.02M | 59.96% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
XOMA News
- 12 days ago - XOMA Royalty Completes Sale of Kinnate Pipeline Assets - GlobeNewsWire
- 18 days ago - BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3 - Accesswire
- 18 days ago - XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist - Seeking Alpha
- 24 days ago - XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference - GlobeNewsWire
- 5 weeks ago - XOMA Royalty Declares Quarterly Preferred Stock Dividends - GlobeNewsWire
- 5 weeks ago - XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements - GlobeNewsWire
- 2 months ago - Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences - GlobeNewsWire
- 2 months ago - XOMA Royalty to Present at Investor Conferences in March - GlobeNewsWire